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doi:10.1016/j.fjs.2012.03.002Summary Esthesioneuroblastoma is a rare neoplasm arising from the olfactory epithelium,
and shows intracranial extension in the advanced disease. We report here a 40-year-old
female, who had initially been diagnosed to have a Kadish stage C esthesioneuroblastoma.
Recurrence presented about 10 months after the first operation, radiotherapy and chemo-
therapy, with pure bilateral subdural extension but without local signs. Although recurrence
is common in advanced esthesioneuroblastoma, such a pattern of presentation is rare, with
only three similar cases reported previously. We discuss the possible pathophysiology of such
an event and propose possible means of prevention.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Esthesioneuroblastoma, also known as olfactory neuro-
blastoma, constitutes about 3% of endonasal neoplasms. It
is thought that the tumor arises from basal olfactory
epithelial stem cells.1,2 The tumor is locally aggressive and
therefore recurs frequently.3,4 However, recurrence usually
occurs in the tumor bed. In this case, the patient presented
with pure bilateral subdural extension of a recurrent tumor,eurosurgery, Department of
Hospital, No.100, Tzyou 1st
807, Taiwan.
m (A.-S. Lieu).
ight ª 2012, Taiwan Surgical Assowhile the previous tumor bed was free of tumor. Such
a pattern of recurrence is rare, with only three similar
cases reported in the literature, and all of these carried
a poor prognosis.2,5 Therefore, we discuss here the possible
pathophysiology of such an unusual presentation in the
hope of preventing its occurrence in the future.
2. Case report
A 40-year-old female presented to our emergency depart-
ment in January 2009 because of a rapid deterioration of
visual acuity within a week, associated with frontal head-
ache, eye pain, nasal congestion, nasal pain, and anosmia.
Brain computed tomography (CT) and magnetic resonance
imaging (MRI) revealed a huge tumor extending from theciation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1 Modified Kadish staging system.6,7
Stage Characteristic
A Disease confined to nasal cavity
B Disease confined to nasal cavity and one or more
paranasal sinuses
C Disease extending beyond nasal cavity or paranasal
sinuses; including involvement of orbit, skull base
or intracranial cavity
D Cervical lymph nodes or distant metastasis
Subdural extension of esthesioneuroblastoma 119frontal base into the orbital and nasal cavities with asso-
ciated destruction of bony structures (Fig. 1). Bilateral
encasement of the optic nerves was observed.
The intracranial portion of the tumor was evacuated
totally via bilateral frontal craniotomy. The arachnoid
membrane was preserved carefully during resection of the
tumor. Further dissection of the intraorbital and intranasal
tumor was achieved through the skull base. A histopatho-
logical study of the specimen confirmed the diagnosis of
esthesioneuroblastoma, Hyam grade III. The lack of
metastasis was deemed consistent with modified Kadish
stage C disease (Table 1).6,7
The patient was discharged uneventfully 10 days after
surgery. She was then treated by chemotherapy using
cisplatin and etoposide, and radiotherapy with a total dose
of 60 Gy in 30 fractions over the resection area.
The patient supported the treatment well and led an
independent day-to-day life thereafter. Unfortunately,
about 10 months later a generalized seizure was noted. In
addition, thereafter, there were also frequent headaches,
vomiting, general weakness and memory impairment. The
condition was complicated by progressive upper back pain.
Imaging studies revealed no local recurrence of the tumor
in the previous operative field, but did show enhancing
masses involving the subdural spaces of fronto-parietal
areas on both sides with perifocal edema (Fig. 2). T1, T4
and T6 vertebral metastases were also observed, with
stenosis caused at the T4 level. The patient underwent
craniotomies with bilateral subdural tumor removal and T4
laminectomy. A histopathological study confirmed the
diagnosis of metastatic esthesioneuroblastoma. Chemo-
therapy and radiotherapy were continued, but the patient
died about 2 years after her first diagnosis.3. Discussion
Although esthesioneuroblastoma can show leptomeningeal
metastasis and intracranial invasion in advanced disease,
such a pure subdural extension without local manifestationsFigure 1 Computed tomography and magnetic resonance imagin
sinuses with destruction of the cribiform plate, lamina papyracea,
cavities, and nasal cavities.is rare. Murakami et al in 2005 and Capelle et al in 2008
have each reported cases of recurrent esthesioneuro-
blastoma shown as diffuse subdural extension.2,3 While
Tamase et al reported a case of recurrent esthesioneuro-
blastoma outside the initial field of radiation with
progressive dural invasion. Our case resembled the latter in
that no recurrent tumor was noted within the previous
resection field. A review of the cases reported suggested
that they all belonged to Kadish stage C disease during
initial presentation, and Hyam’s grades II to III under
histological examinations. The patients died of the original
disease 8 years, 2 years, and 2 years after the first diagnosis
in the cases of Murakami et al, Capelle et al and our
patient, respectively. Therefore, close post-operative MRI
or CT scan follow-up is mandatory in advanced cases,
because such a pattern of disease appears to carry a poor
prognosis.
There are an increasing number of reports supporting
the effectiveness of combined surgery and radiotherapy for
treating esthesioneuroblastoma. In Dulguerov’s 2001 meta-
analysis, the 5-year overall survival for patients treated
with surgery plus adjuvant radiotherapy was 65%, in
contrast to 48% for those treated by surgery alone.3 A series
from the University of Virginia gave a more promising
result, with an 8-year median overall survival of 80.4%
achieved in patients undergoing craniofacial resection with
adjuvant therapy (radiotherapy  chemotherapy).8 Chaog revealed an expansile mass bilaterally involving the ethmoid
sphenoid sinus, and invasion of the frontal base, medial orbital
Figure 2 Magnetic resonance imaging revealed bilateral subdural extension of recurrent tumor without local recurrence (white
arrows).
120 B.-K. Lua et al.et al reported the 5-year local control rate of 87.4% for the
combination of surgery and radiotherapy compared to
51.2% for irradiation alone.9 In that series, the author even
suggested that with adjuvant radiation therapy, the
surgical margin did not influence local tumor control,
showing that esthesioneuroblastoma is radiosensitive in
nature. In both our case and that reported by Tamase et al,
the tumor did not recur in the previous irradiation field.
This could indicate the radiosensitivity of the tumor and
the effectiveness of adjuvant radiotherapy in treating the
disease, and highlight the importance of the setting of the
irradiation field.
Since the introduction of the craniofacial approach in
1970s, the 5-year survival at the University of Virginia
increased from 37.5% to 82%.10 There is an increasing
interest in endoscopic surgery, and its role is currently being
evaluated. As seen in our case, a trans-basal approach can
also achieve a promising result in removing the tumor. With
any approach, the arachnoidmembrane should be preserved
carefully and as much as possible to prevent cerebrospinal
fluid (CSF) dissemination. As the tumor is friable, the tumor
cells can spread diffusely along the subdural space during
the first operation, and cause subdural extension when it
recurs. Therefore, we suggest that unnecessary irrigation of
the resection field should be avoided in order to prevent
such a complication. In addition, post-operative subdural
hematoma could also promote such a recurrence.2 Thus
meticulous hemostasis is mandatory. During the operation of
our case, the patient was placed in a supine position, with
the neck extended. This made the fronto-parietal areas the
dependent sites during tumor excision, and possibly
contributed to tumor seeding. Therefore we suggest that
avoidance of neck hyperextension might be helpful in this
respect.
4. Conclusions
According to the literature, combined surgery and radio-
therapy is presently the most effective treatment strategyfor esthesioneuroblastoma. For advanced disease, close
MRI or CT scan follow-up is recommended. The absence of
recurrent tumor within the previous irradiation field may
indicate the radiosensitivity of esthesioneuroblastoma.
Certain preventive steps such as preservation of arachnoid
membrane, only necessary irrigation, meticulous hemo-
stasis, and avoidance of neck hyperextension should be
taken in order to prevent subdural extension of the recur-
rent tumor.References
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